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Abstract: Recently tuberculosis has shown a
speedy worldwide spread. The incidence of
drug-resistant Mycobacterium tuberculosis is
increasing in almost all industrialized and
developing countries. The epidemiology of
multiple drug resistance varies in different
regions and countries.

Department of Microbiology and Clinical
Microbiology, Faculty of Medicine, Ege
University, ‹zmir - TURKEY

The aim of this study was to determine the
activities of first-line (isoniazid, rifampin,
ethambutol and streptomycin) and second-line
(kanamycin,
para-aminosalicylic
acid,
ethionamide
and
capreomycin)
antituberculosis drugs on 100 various clinical
isolates of M. tuberculosis. Mycobacterium
tuberculosis ATCC 27294, ATCC 35838,
ATCC 35825 and ATCC 35837 were used for
internal quality control.
First-line drug resistant strains were isolated
from 10 clinical specimens. Six of them

Introduction
Tuberculosis (TB) has been spreading worldwide in
recent years. More and more singletons seem to indicate
that the incidence of drug-resistant Mycobacterium
tuberculosis is increasing in almost all industrialized and
undeveloped countries. One-third of the world population
is infected with this pathogen, and eight million new
tuberculosis cases occur each year. Moreover, nearly
three million people die annually of tuberculosis, making
it the leading cause of death due to an infectious agent
worldwide (1,2).
TB is a widely spreading infectious disease in Turkey
also. Since 1985, there have been no extensive studies on
a national level concerning the epidemiologic features of
tuberculosis. There is no definite data about the current
prevalence in Turkey (3). In an investigation carried out
in 80,000 persons, tuberculosis prevalence was found to
be 3.58‰ between 1981 and 1982 in Turkey (4).
According to this rate, Turkey is in the group of
hyperendemic countries. According to the data published

showed resistance to a single drug and four to
more than one first-line drug. All of the
single-drug resistant strains were resistant to
isoniazid. Of 100 isolates, 56 were resistant
to capreomycin, 41 to kanamycin, 12 to paraaminosalicylic acid and four to ethionamide.
All of the first-line drug-resistant strains were
found to be susceptible to para-aminosalicylic
acid and ethionamide.
In view of the above findings, we suggest that
clinicians should be well-informed about the
current local epidemiology of tuberculosis,
and health care institutions should maintain
up-to-date drug susceptibility data on the local
isolates of M. tuberculosis.
Key Words: Mycobacterium tuberculosis,
isoniazid,
rifampin,
ethambutol,
streptomycin, kanamycin, para-aminosalicylic
acid, ethionamide, capreomycin, susceptibility

by the Health Ministry Presidency Department of
Struggle Against Tuberculosis, tuberculosis incidence
increased between 1980 and 1985 and decreased
between 1985 and 1992 (5).
The modern era of tuberculosis is characterized by an
increase in the number of cases of infections with multiple
drug resistant (MDR) M. tuberculosis. The rising
prevalence of MDR strains has resulted in outbreaks and
individual cases that are only marginally treatable and
often fatal. MDR tuberculosis (MDRTB) is caused by a
strain of M. tuberculosis that is resistant to two or more
antituberculosis drugs. Many investigators suggest that
the strain should be resistant to isoniazid and rifampin to
be qualified as MDR (6,7).
The local epidemiology of MDRTB varies throughout
the world. The most significant predictor of MDRTB in all
previous studies was history of treatment with
antituberculosis drugs. Inadequate therapy remains the
most common mechanism by which resistant organisms
develop in tuberculosis clinics in many parts of the United
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States (6). A susceptible strain of M. tuberculosis may
become resistant to multiple drugs within a matter of
months because of circumstances of monotherapy, erratic
drug ingestion, omission of one or more of the prescribed
agents, suboptimal dosage, poor drug absorption, or
insufficient number of active agents in a regimen. In
addition, patients with cavitary lesions have a high
frequency of resistance, presumably because they
harbour greater numbers of mycobacteria (8). Other
high-risk populations for drug resistant tuberculosis
include human immunodeficiency virus (HIV) infected and
acquired immunodeficiency syndrome (AIDS) patients,
immunocompromised individuals, socioeconomically
indigent individuals and inner-city dwellers, including
homeless incarcerated individuals (6).
Mortality from MDRTB exceeds 80% in persons
infected with HIV but is also high in patients free of HIV.
The management of MDRTB is complicated by the lack of
methods for rapid detection of resistant strains of M.
tuberculosis (7).
The prevalence of drug-resistant organisms among
patients with pulmonary tuberculosis in Turkey has
steadily increased from 22% to 39% in the past five
decades. Inadequate therapy remains the most common
mechanism by which resistant organisms develop in
tuberculosis clinics in many parts of Turkey (9).
In another article, chosen from 67 articles reviewed
by Ucar, it was indicated that in the last 40 years there
has been no difference in the rate of resistance to firstline drugs. According to the author, standard drug
concentrations were not used in the articles which were
included in the investigation (10).
Drug-resistant strains of M. tuberculosis can be
transmitted by infected individuals or resistance can be
acquired during-therapy for drug susceptible diseases. At
least until susceptibility test data are available, the
recommended initial treatment for tuberculosis consists
of isoniazid, rifampin, pyrazinamide, and either
ethambutol or streptomycin. Resistance has led to
variations in this regimen that sometimes include more
toxic alternative drugs including ethionamide,
aminosalicylic acid, kanamycin and capreomycin, as well
as ciprofloxacin and ofloxacin. The drug regimens used
for retreatment usually include alternative drugs. Success
in treating drug-resistant tuberculosis varies (8,11).
Recent outbreaks of tuberculosis with MDRTB have
indicated an urgent need for new drugs.
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The aim of this study was to determine the activities
of first-line and second-line antituberculosis drugs against
100 strains of M. tuberculosis isolated from various
clinical specimens.

Materials and Methods
Mycobacterial strains. One hundred strains of M.
tuberculosis isolated from various clinical samples in the
Clinical Microbiology Laboratory of Ege University
Hospital were included in this study. All strains were
isolated by culturing on Löwenstein-Jensen slants and by
use of the MB/BacT (Organon-Teknika) automated
system. Organisms were identified to species level by
standard methods (12). M. tuberculosis ATCC 27294,
ATCC 35838, ATCC 35825 and ATCC 35837 were used
for internal quality control.
Antimicrobial agents. Standard laboratory powders
with known potency were used. Isoniazid (INH), rifampin
(RIF), ethambutol (ETB), streptomycin (STR), kanamycin
(KM), para-aminosalicylic acid (PAS), ethionamide (ETH)
and capreomycin (CAP) were obtained from Sigma. The
following drugs and concentrations were included in agar
proportion susceptibility tests: INH 0.2 and 1 µg/ml, RIF
1 µg/ml, ETB 5 µg/ml, STR 2 µg/ml, KM 5 µg/ml, PAS 2
µg/ml, ETH 5 µg/ml and CAP 10 µg/ml. Antibacterial
activity was determined by an agar dilution technique
using Middlebrook’s 7H10 agar. Standard Middlebrook
7H10 agar and oleic-albumin-dextrose-catalase (OADC)
enrichment were used to prepare all drug-containing
media (12). Stock solutions of the agents were prepared
on the day of testing according to the recommendations
of the manufacturers.
Susceptibility testing. Standard agar proportion
dilution methods were used in this study (12). Colonies
from a Löwenstein-Jensen tube were homogenized in
phosphate buffered saline (pH 7.0) to achieve turbidity
equal to a McFarland 1.0 standard, corresponding to
9
approximately 10 CFU/ml. This bacterial suspension was
used for agar dilution by inoculating plates with a Steers
replicator. In the agar proportion dilution methods, an
isolate was classified as susceptible to a drug if the
number of colonies that grew on the drug-containing
plate was < 1% of the number of colonies that grew on
a control plate without the drug, partially resistant if the
number was between 1 and 10%, and resistant if the
number was >10%. In cases where two drug
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concentrations were tested in the agar proportion
dilution method, an isolate was classified as partially
resistant if it exhibited resistance at the lower
concentration but was susceptible at the higher of the
two concentrations tested.

resistant only to CAP (Table 2). All of the four isolates
that were resistant to more than one first-line drug were
susceptible to second-line drugs.

Results

Discussion

The antimycobacterial activities of the first- and
second-line drugs are summarized in Tables 1 and 2.
First-line drug-resistant strains were isolated from 10
(10%) clinical samples. Six of them (6%) were resistant
to a single drug and four (4%) were resistant to more
than one first-line drug [INH and STR, INH and ETB, ETB
and STR, RIF and STR] (Table 2). All single drug-resistant
strains were resistant to INH.

TB incidence is still increasing and the most serious
aspect of the problem is the recent outbreaks of MDRTB
which pose an urgent public health problem and require
rapid intervention. When the infecting organism is
resistant to both INH and RIF, the duration of treatment
is prolonged from six months to 18-24 months, and the
cure rate decreases from nearly 100% to less than or
equal to 60%. The selection of drugs available for
treating TB is limited, which makes the treatment of
drug-resistant cases particularly difficult (13). In patients
infected with MDRTB, at least five drugs are needed to
protect against additional acquired resistance. For
patients with HIV infection or AIDS in their areas, a six-

Of the second-line drug-resistant strains, 56 were
resistant to CAP, 41 to KM, 12 to PAS and four to ETH.
Two of the six isolates which were resistant to INH
were susceptible to second-line drugs, three of them
were resistant to KM and CAP and one of them was

Resistant to
second-line
drug

CAP
KM
ETH
PAS

All of the first-line drug-resistant strains were found
to be susceptible to PAS and ETH.

Resistant to one
first-line drug
(n=6)

Resistant to more
than one first-line
drug (n=4)

Drug sensitive
tuberculosis
(n=90)

TOTAL

4*
3
-

-

52
38
4
12

56
41
4
12

Table 1.

Resistance to first- and second line
drugs (n = 100).

Table 2.

Resistance of the first-line drugresistant strains to second-line
drugs.

* Isolates, which were resistant to CAP, include the three KM-resistant isolates.

Samples

1
2
3
4
5
6
7
8
9
10

Resistant to
one first-line drug
and more than one first-line drug
INH
INH
INH
INH
INH
INH
INH, STR
INH, ETB
ETB, STR
RIF, STR

Resistant to
second-line drug

KM, CAP
KM, CAP
KM, CAP
CAP
-
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to 14.3%, RIF from 5.8% to 12%, ETB from 2.2% to
8.5 and STR from 2.4% to 11.4% (16). In Sureyyapasa
Chest Disease Hospital, the rate of resistance to either of
the first-line drugs was determined to be 11.2% in 1980,
14.5% in 1986, 18% in 1987 and 17.4% in 1988 (25).
According to Goral et al. (23), the total rate of resistance
to first-line drugs increased from 31% in 1982-1985 to
45.7% in 1985-1987. In an analysis by Ucar, 67 articles
in which resistances of first-line and second-line drugs
were reviewed, primary rate resistances to first line
drugs were determined to be 9% in STR, 4% in RIF, 5%
in INH and 0.4% in ETB and primary total rates of
resistance were determined to be 16%, 11%, 13% and
3%, respectively. It was concluded that there has been no
statistically significant difference in the rates of drug
resistance over the last 40 years. Rates of secondary
resistance are given as 9% in STR, 7% in RIF, 14% in
INH and 0% in ETB. Secondary total rates of resistances
are given 30%, 25%, 35% and 13%, respectively. The
resistance rate against another drug was indicated as
45%, against two drugs as 21%, and 13% against three

drug regimen based on the local susceptibility pattern of
the patient-infecting organisms is defined (8).
The aim of the present study was to determine the
activity of first- and second-line antituberculosis drugs on
clinical isolates of M. tuberculosis. The rate of
susceptibility to first-line drugs varies in different parts of
the world, including Turkey. Studies on the rates of the
resistance to first-line drugs which were carried out in
different areas of Turkey are summarized in Table 3. In
the reports in which standard drug concentrations were
used the number of strains studied varied between 50
and 393. The total rate of resistance varies between
14.3% and 33.7%, which resists at least one first-line
drug (total resistance) and the rate of MDRTB varies
between 6% and 56.2% (14-24). When the rates of
resistance were inspected year by year between 1987 and
1999, it was seen that the rate of resistance to either of
the first-line drugs increased from 19.2% in 1987 to
22.7% in 1991. When the rates of resistance to drugs
were evaluated one by one between 1987 and 1991, it
was seen that the resistance to INH changed from 2.9%

Table 3.

Resistance to first-line drugs in various region of Turkey.
Drug concentration in medium

City-Year (Reference)

Number of

Resistant to first-line drugs (%)

Methods

strains

Primary-Secondary resistant/
INH

RIF

STR

ETB

INH

RIF

STR

ETB

Total resistant (%)

MDRTB (%)

SAMSUN 1998 (14)

50

Proportion1

0.2-1

1.0

2.0

2.0-10

6

4

2

8

- / 20

6%

ANKARA 2000 (15)

100

Proportion1

0.2

1.0

2.0

5.0

19

18

9

13

-/ 27

12

BACTEC

0.2

2.0

6.0

7.5

19

17

10

13

SIVAS 1987-1991 (16)

226

Proportion2

GAZIANTEP 1994-1998 (17)

199

BACTEC

ISTANBUL 1995-1997 (18)

32

Proportion2

ADANA 1993-1995 (19)

393

BACTEC

EDIRNE 1996 (20)

70

Proportion1

-

-

-

-

10.2

8

8.5

4.9

- / 14.3-22.7

-

0.2

2.0

6.0

7.5

10.6

0.5

2

4.5

- / 17.6

15.6 (two drugs)

0.2-1

20-40

4-8

2-3

100

100

22

15

Secondary resistant to

56.26 (two drugs)

32 strains

15.6 (three drugs)

0.2

2.0

6.0

7.5

5.08

3.82

4.58

1.01

- / 32.31

17.81

0.2-1

1

2-10

5

30 P

11 P

32 P

9P

52-62 / INH 30 - RIF 11 –

7

31 P

12 P

50 P

19 P

STR 39 - ETB 13

12 (three drugs)

IZMIR 1986-1988 (21)

59

Proportion2

0.2

20

4

2

6.77

5.08

10.1

0

- / 22.01

IZMIR 1989-1992 (22)

63

Proportion2

0.2

20

4

2

9

27

32

3

41 (total primary resistant)

22.5

BURSA 1990 (23)

193

Proportion2

0.2-1

20-40

4-8

5-10

23.8

6.7

16.6

4.1

- / 33.7

20 (two drugs)

MANISA 2000 (24)

75

Proportion1

1.0

1.0

2.0

6.0

16

12

20

13

- / 25

20.33

9.2 (three drugs)
6 (two drugs)
2 (three drugs)
1

Middlebroke 7H10 +OADC medium

2 Löwenstein/Jensen medium
P Primary resistant
S Secondary resistant
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drugs (10). Our results show that of 100 M. tuberculosis
strains, 10 (10%) were resistant to at least one of the
first-line antituberculosis drugs. Six (6%) of these were
resistant to one drug (INH), while four (4%) were
resistant to more than one. Our total resistance rates are
lower than the general resistance rates found so far in
Turkey. This difference can be attributed to several
features of the patient population. Our patients were
from a relatively higher socioeconomic level and were
receiving directly observed therapy (DOT). In contrast,
previous studies in Turkey included socioeconomically
indigent outpatients who were admitted to State
Tuberculosis Dispensaries and the compliance of the
patients was questionable.
The drug resistance of tubercle bacilli has
consequently led to variations in therapy regimens that
sometimes include more toxic alternative drugs including
ethionamide, para aminosalicylic acid, kanamycin and
capreomycin. The rate of susceptibility to second-line
drugs varies in different parts of the world, including
Turkey. There are few articles examining the resistance
to second-line drugs in Turkey. In research on 32 MDRTB
strains, the resistance to ETH was found to be 65.6%
(20 µg/ml) and 56.2% (40 µg/ml), to KN 9.3% (20-30
µg/ml), and to CAP 12.5% (20 µg/ml) and 6.2% (40
µg/ml) (18). In Ucar’s analysis, five studies were
examined and primary resistance to PAS between 1963
and 1983 was found to increase from 3.6 to 8%.
Secondary resistance to PAS between 1963 and 1984
was found to increase from 6 to 15%. Primary rates of
resistance to ETB between 1990 and 1993 were found
to be 0-11% and secondary resistance rates were 7-28%
in the same years (10). In previous studies, KM resistance
was found to be 1.1% in Thailand, 25% in India and 6%
in Mexico, and in the Russian Federation there is an
increase of 3-6% annually. The resistance in ETH was
found to be 65.1% in India, 7% in Mexico and 1.7% in
Italy and all MDRTB cases in Ethiopia were sensitive to
ETB. In Mexico the resistance to PAS was 9% while in
England resistance to CAP was 0.3% (26-31). The levels
of resistance to second-line drugs were 41% for KM,
56% for CAP, 4% for ETB and 12% for PAS in this
study. Multidrug-resistant isolates were susceptible to all
second-line drugs. All isolates that were resistant to firstline drugs were susceptible to PAS and ethionamide.

Isolates resistant to KM were also resistant to CAP. The
resistance rates to KM and CAP were higher. This may be
the result of exended use of aminoglycosides such as
amikacin and gentamycin for the empirical treatment of
lower respiratory tract infections. The early period of
tuberculosis can be misdiagnosed as a nonspecific
infection of the lower respiratory tract, and thus the
difference may be due to the irrational unlimited use of
aminoglycosides in the treatment of nonspecific
infections. M. tuberculosis can develop resistance to KM
as a result of cross-resistance between the
aminoglycosides. This situation may explain why the KM
resistance rate is high among our isolates. Significantly,
there is no cross-resistance between KM and STR.
However, cross-resistance between KM and CAP can
occur. This may be an explanation for the lower
resistance rate of STR found in this study. This may also
explain why the resistance rates of both KM and CAP are
high. These findings show that ETB and PAS can be good
alternatives, particularly in MDRTB cases.
Most countries affected by the HIV pandemic and
increasing prevalence of tuberculosis also have poorly
functioning tuberculosis control programmes and cannot
afford the antituberculosis drug regimens that are most
effective for preventing MDR disease as well as treating
it. Thus, the stage is being set for a substantial increase
in the incidence of drug-resistant tuberculosis in many
countries. If this is allowed to occur, the developing
countries will not be the only ones affected. International
travel, migration between countries and trade with
emerging economies continue to increase, and thus the
proportion of tuberculosis cases in developed countries
that originate from developing countries will increase as
well (32). In the light of these findings, two sugestions
can be put forward. First, clinicians should know the local
epidemiology of tuberculosis. Second, health care
institutions (hospitals and public health departments)
should maintain up-to-date drug susceptibility data on the
local isolates of M. tuberculosis.
Correspondence author:
Candan Ç‹ÇEK SAYDAM
Ege University Faculty of Medicine,
Department of Microbiology and Clinical Microbiology,
35100, Bornova, Izmir - TURKEY
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